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SUMMARY
Affinity maturation of antibody responses depends on somatic hypermutation of the immunoglo-
bulin V genes. Hypermutation is initiated specifically in proliferating B cells in lymphoid germinal
centres but the signals driving this process remain unknown. This study identifies signals that
promote V gene mutation in human germinal centre (GC) B cells in vitro. Single GC B cells were
cultured by limiting dilution to allow detection of mutations arising during proliferation in vitro.
Cells were first cultured in the presence of CD32L cell transfectants and CD40 antibody (the ‘CD40
system’) supplemented with combinations of cytokines capable of supporting similar levels of
CD40-dependent GC B-cell growth [interleukin (IL)-10+IL-1b+IL-2 and IL-10+IL-7+IL-4].
Components of the ‘EL4 system’ were then added to drive differentiation, providing sufficient
immunoglobulin mRNA for analysis. Analysis of VH3 genes from cultured cells by reverse
transcription–polymerase chain reaction (RT–PCR)-based single-strand conformation polymorph-
ism indicated that the combination IL-10+IL-1b+IL-2 promoted active V gene mutation whereas
IL-10+IL-7+IL-4 was ineffective. This was confirmed by sequencing which also revealed that the
de novo generated mutations were located in framework and complementarity-determining regions
and shared characteristics with those arising in vivo. Somatic mutation in the target GC B-cell
population may therefore be actively cytokine driven and not simply a consequence of continued
proliferation. The experimental approach we describe should facilitate further studies of the
mechanisms underlying V gene hypermutation.
INTRODUCTION
One of the hallmarks of the T-dependent immune response is
the increased affinity of antibodies produced upon repeated
antigenic challenge.1,2 This affinity maturation is attributable
to a combination of somatic hypermutation in the immuno-
globulin V genes and selection of those B cells which
consequently produce immunoglobulin with an improved
affinity for antigen.2–4 While understanding of the mechanisms
of the B-cell selection process are now well advanced (reviewed
in 5), the mechanisms underlying V gene-directed somatic
hypermutation are still largely unknown.
Molecular aspects of the somatic hypermutation process
have been studied in immunized mice by using polymerase
chain reaction (PCR) amplification of immunoglobulin germ-
line families whose use is antigen-restricted.1–3,6,7 Such studies
have revealed that the process produces mainly single point
mutations and has a number of characteristic features
including a preference for transitions over transversions, strand
polarity, and targeting of mutations to hotspots (reviewed in 4).
Study of hypermutation during immune responses in man,
however, is more difficult. Clonal analysis of some human
responses has been achieved by making hybridomas from
Epstein–Barr virus (EBV)-transformed B cells from immunized
donors.8 Transgenic mice bearing human immunoglobulin
miniloci have been used as an alternative to immunization to
study somatic mutation during antibody responses in
humans.9,10 This approach however, has the disadvantages
that only a limited repertoire of human V regions can be
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introduced resulting in bias of the germline usage and that
murine, not human, hypermutation machinery is used to
induce the mutations.
Sequence analysis of B-cell subsets and single B cells picked
from histological sections of peripheral lymphoid tissues
indicates that somatic hypermutation is initiated in the rapidly
proliferating centroblasts in the germinal centres (GC) of B-cell
follicles.11–13 The molecular characteristics of somatic hyper-
mutation have been studied in human follicular and Burkitt’s
lymphoma cell lines because some show appreciable rates of
spontaneous mutation in culture.14,15 Attempts to study the
mutation process in normal centroblasts however, have been
hampered by the fact that GC B cells are programmed for
apoptosis and die rapidly upon culture.16
Previously we have shown that single human GC B cells can
be maintained in vitro by culture with mouse EL4 thymoma
cells (in the ‘EL4 system’,17,18). Although these culture
conditions initially sustain proliferation and maintain the
phenotypic features of the freshly isolated GC B cells, they later
promote progressive differentiation to plasma cells and,
importantly, the cells do not accumulate somatic mutations.
Cycling human GC B cells can be maintained for longer
periods without terminal differentiation in bulk cultures
supported by CD32 transfected mouse fibroblasts and CD40
antibody (the ‘CD40 system’,19) supplemented with appro-
priate combinations of cytokines.20
Here we have combined these two in vitro culture systems in
order to study the signals regulating somatic hypermutation in
human GC B cells. We used reverse transcription (RT)–PCR-
based single-strand conformation polymorphism (SSCP)
analysis to screen for mutational activity and confirmed
mutations in positive clones by sequencing. We show that of
two cytokine combinations that can maintain GC B-cell
proliferation in CD40 stimulated cultures only one (IL-
10+IL-1b+IL-2) sustains active V gene-directed mutation.
The characteristics of the mutations observed are consistent
with those reported to be found in vivo.
MATERIALS AND METHODS
Monoclonal antibodies
AC2 (CD39) and G28-5 (CD40) were produced from
hybridomas in the Department of Immunology, University
of Birmingham (Birmingham, UK). G28-5 hybridoma was
obtained from American Type Culture Collection (ATCC;
Rockville, MD). The monoclonal antibodies were purified by
ion exchange chromatography on DE52 cellulose (Whatman
Ltd, Madison, UK). Non-conjugated anti-human immunoglo-
bulin D (IgD) and R-phycoerythrin (RPE)-conjugated CD38
and CD3 antibodies were purchased from Becton-Dickinson
(San Jose, CA). Fluoroscein isothiocyanate (FITC)-conjugated
CD19 antibody and anti-IgD were purchased from Dako A/S
(Glostrup, Denmark).
Cells
B cells from human tonsils were purified as previously
described.18,21 The tonsils were obtained from patients under-
going routine tonsillectomy at Lund University Hospital
(Lund, Sweden) or at Malmo¨ Academic Hospital (Malmo¨,
Sweden). Briefly, tonsils were minced and mononuclear cells
isolated using density gradient centrifugation on Ficoll-
Isopaque (Pharmacia, Uppsala, Sweden). T cells were removed
by two rounds of rosetting with neuraminidase-treated sheep
red blood cells.22 B cells were then fractionated by centrifuga-
tion on isotonic Percoll (Pharmacia Biotech) 60% (v/v) in
RPMI. The buoyant cell fraction which was enriched for GC B
cells was depleted of contaminating resting B cells and
follicular mantle cells by negative selection using anti-IgD
and CD39 antibody coated onto magnetic beads (Dynal,
Norway). The resultant GC B fraction, defined as
CD38+ IgD– CD19+ was <3% CD38– IgD+, >96%
CD19+ and <0.3%. CD3+ T cells. The expression of CD19,
CD38 and IgD on each population was estimated using flow
cytometry as previously reported.18
Cell cultures
Culture medium was RPMI-1640 (Gibco, Paisley, UK)
supplemented with 10% calf serum, 2 mM L-glutamine, 1%
non-essential amino acids, 50 mg/ml gentamicin (Biological
Industries, Hamek, Israel). GC B cells were seeded at a limiting
dilution to give one cell/well in starting cultures for efficient
evaluation by SSCP. GC B cells were first cultured for five days
on c-irradiated (5000 rad) human CD32 transfected murine L
cells (DNAX Research Institute of Cellular and Molecular
Biology; Palo Alto, CA) (2r104/well) with CD40 antibody
(G28-5; 0.5 mg/ml) in 100 ml complete medium. The cultures
were set up in flat-bottomed 96-well plates (Costar, Cambridge,
MA). Cultures were supplemented with two different combina-
tions of recombinant human cytokines: (i) IL-10, IL-1b and IL-
2 or (ii) IL-4, IL-7 and IL-10 (R & D Systems Ltd, Oxford,
UK), respectively, previously shown to promote optimal
growth conditions for the cells preserving the GC B cell
phenotype.20 Cytokines were used at concentrations previously
published to give optimal synergistic effect on GC B cells in the
CD40 system.20 After five days of culture, the wells were
supplemented with c-irradiated (5000 rad) murine EL4 thy-
moma cells (50r103/well), 100 U/ml IL-2 (Genzyme, Cam-
bridge, MA), 3 ng/ml 4-phorbol 12-myristate 13-acetate
(PMA; Sigma, Poole, UK) and 50 mM 2-mercaptoethanol
(Merck, Darmstadt, Germany) together with 5% T-cell
replacing factor [pokeweed mitogen (PWM)-TRF23]. After
an additional five days of culture with the EL4 cells, the
expanded B-cell clones were washed once in ice-cold phosphate
buffered saline and lysed in Tris–HCl buffered 4 M GuSCN,
pH 7.5 for RNA extraction.
Table 1. Oligonucleotide primers used for RT-PCR analysis of V genes
SGS13 5k-CTG AGG AGA CGG TGA CCA-3k JH universal 3k
SGS14 5k-A(AG)G (AT)AG (TC)CC T(TG)(TG) (GA)C(GC) AGG CAG-3k Consensus,G,A,M H chain, aa141–147 3k
SGS15 5k-GAG GTG CAG CTG GTG GAG (AT)CT-3k VH3 5k FR1, aa1–7
SGS16 5k-TCC CTG AGA CTC TCC TGT-3k VH3 FR1 reamplification, aa17–22
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RT-PCR analysis of V genes
mRNA was extracted according to a previously described
protocol23 using magnetic capture on oligo-d(T)25-beads.
Following magnetic capture (MPC-9600; Dynal) the oligo-
d(T)25 bound poly-A RNA was reverse transcribed using
murine Moloney leukaemia virus (M-MLV) for 1 hr at 37u in a
20-ml reaction. Five ml of the cDNA reaction was amplified in a
nested PCR using VH3-specific primers (Table 1). Primers were
designed to bind 5k in framework region 1 (FR1) (SGS15) and
3k using a consensus for IgM, A and G (SGS14). Each cycle
(total of 25) consisted of denaturation (96u, 30 s), primer
annealing (55u, 30 s) and DNA synthesis (72u, 30 s (120 s for
final cycle)). One ml of this PCR product was reamplified (25
cycles) using a 5k primer downstream in FR1 (SGS16) and a
universal 3k primer in the J segment (SGS13). The products
were then analysed on a preparative 4.5% Nusive GTG low
melting point agarose gel and ethidium bromide was used for
visualization. Lanes containing positive bands were cut out and
purified from the gel (Wizard, Promega, Madison, WI). All
PCR reactions were performed in a Perkin Elmer Gene Amp
PCR system 2400.
Single-strand conformation polymorphism (SSCP) analysis
SSCP24 was used as a rapid screen for mutations in the PCR-
amplified samples. The analysis was performed using 1 ml of
PCR-amplified and gel-purified product double-stranded DNA.
Briefly, heat-denatured and ice-cooled PCR product was
separated on a 12.5% native polyacrylamide PHAST gel using
the PhastSystem2 (Pharmacia LKB Biotechnology, Uppsala,
Sweden) with native buffer strips (native polyacrylamide gel
electrophoresis; PAGE). The separated strands were detected
with silver staining. The separation was run according to
Application Note no. 383 (PhastSystem2) and the silver staining
according to Application Note no. 210 (PhastSystem2).
In order to confirm the sensitivity of SSCP for mutational
analysis cDNA from two closely related human hybridomas
with known Igk gene sequences was analysed. These hybrido-
mas (anti-TF25; TF=Thomsen Friedenreich) which differed by
one triplet in their IgV sequences were mixed at different cell
ratios, mRNA prepared from the mixtures and cDNA obtained
by VH3 specific nested PCR.
Cloning and sequence analysis
PCR-products for sequencing were cloned into a pGEM1-T
vector using T/A cloning approach (Promega). To avoid
further analysis of cloned Taq-errors, the originality of cloned
PCR products were re-analysed after cloning using SSCP to
identify the original banding-pattern of the cloned product. All
sequencing was performed with BigDye2 (Perkin Elmer)
reaction using M13 forward and reverse primers. The samples
were collected and analysed on a ABI Prism 377 DNA
Sequencer (Perkin Elmer).
Statistical analysis
Cell densities were calculated from the number of positive PCR
products, reflecting outgrowth of VH3 positive cell clones, in
relation to total number of wells screened.26 SSCP data were
analysed using the Poisson approximation to the binomial
distribution and the significance assessed by the x2 test.
RESULTS
Single cell culture of human GC B cells
We seeded cultures with single GC B cells by limiting dilution26
to allow detection of mutations arising in clonally related cells
during proliferation in vitro. For the first 5 days single GC B
cells were cultured in the ‘CD40 system’ supplemented with two
different combinations of cytokines, each capable of support-
ing similar levels of CD40-dependent GC B-cell growth.20 In
order to obtain sufficient mRNA from the clones for RT–PCR-
based SSCP analysis components of the ‘EL4 system’17 were
then added to cultures to promote terminal differentiation.18
The details of the culture system employed to maintain GC
B cells are outlined in Fig. 1. EL4 system components were
added after 5 days culture in the CD40 system and mRNA was
extracted after a further 5 days. These culture intervals were
chosen in the light of previously reported kinetics of DNA
synthesis and growth in the two systems when used indepen-
dently for GC B-cell culture.18,20 RNA was amplified for VH3
immunoglobulin by nested RT–PCR and double-stranded
PCR products were analysed for mutations by SSCP. The
appearance of more than two bands in SSCP analysis of PCR
products as performed in this study is indicative of either
mutation of the clone or the presence of more than one
Figure 1. Schematic illustration of culture system employed. Germinal centre B cells, at limiting dilution, were cultured for five days
with CD32 transfectants and CD40 antibody supplemented with (a) IL-1b, IL-2 and IL-10 or (b) IL-10, IL-7 and IL-4. After 5 days
EL4 cells, PMA, IL-2, PWM-TRF and 2-mercaptoethanol were added. After a further 5 days of culture, cells were lysed for RNA
extraction and RT–PCR-based SSCP.
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precursor (the likelihood of which follows the Poisson
distribution).
We were able to detect as few as 2.5% hybridoma cells
differing in one triplet in their V regions25 by this approach
(Fig. 2) suggesting that the sensitivity of the assay to detect
mutations was as previously reported for SSCP.27,28
Detection of V gene mutation in cultured germinal centre B
cells
SSCP analysis revealed clear differences between GC B cells
that had been cultured with different cytokine combinations
(Table 2, Fig. 3a,b). PCR products from cultures supple-
mented with IL-10+IL-1b+IL-2 gave a greatly increased
proportion of lanes containing more than two bands. After
analysis of the proportion of cultures that failed to yield PCR
products we concluded that the presence of more than two
bands in those containing IL-10+IL-1+IL-2 was a result of
mutations arising during growth in vitro and not seeding more
than one precursor (P<0.001) (Table 2). Cells cultured with
IL-10+IL-1b+IL-2 gave 32/210 (15%) lanes with multiple
bands compared with 1/90 (1.1%) for those cultured with IL-
10+IL-7+IL-4. The frequency of single cell cultures contain-
ing IL-10+IL-7+IL-4 that gave more than two bands in SSCP
was not significantly different from that which would be
expected by chance (from the Poisson approximation to the
binomial distribution, P>0.3), suggesting no mutations had
occurred, whereas for cultures containing IL-10+IL-1b+IL-2
there was a highly significant difference (P<0.001). Culture of
GC B in the EL4 system alone failed to sustain mutational
activity (Table 2).
Confirmation of immunoglobulin V gene mutations arising
in vitro
In order to determine whether multiple bands in SSCP analysis
of the PCR amplified samples were due to the presence of cells
with different clonal origins growing in a single culture well or
to changes within one clone that occurred during culture as a
result of mutation, the DNA was cloned and sequenced. Before
sequencing, the origin of the clone picked for sequencing was
re-confirmed by SSCP to exclude the possibility of cloned Taq-
errors.
Bands from the representative SSCP-gels in Fig. 3(a) (lane
1, 3 and 5) and Fig. 3(b) (lane 5) (samples from experiment I,
Table 2) were sequenced, as well as some of the lanes
containing multiple bands from cells cultured with IL-
10+IL-1b+IL-2 to confirm differences at the DNA level
between the clones. Table 3 shows that in one experiment two
clones out of three represented material with one and two
mutational differences, respectively. In a second experiment
(Exp. II, Table 3) four of nine clones analysed represented
mutated clones and one to three mutations were found in each
1     2    3     4     5     6     7         8      9    10   11   12
(a)
(b)
(a) 5     10  20   30   40     50    60        70   80    90   100   200
(b)    195  190     -     170  160   150  140        130   120  110   100  0
Figure 2. Sensitivity of SSCP in detecting mutations. SSCP analysis of
cDNA obtained from mixtures of anti-TF hybridomas A and B that
differed in one triplet in their IgV genes was performed as described in
Materials and Methods. The relative numbers of each hybridoma in the
mixtures are shown below each lane. No PCR product was obtained
from hybridoma B in lane 3. As few as five cells of hybridoma A could
be detected in the presence of 195 cells of hybridoma B (lane 1).
1         2        3         4          5          6
1         2        3         4          5          6
(a)
(b)
Figure 3. Representative gels of SSCP-analysis of cultured GC B cells.
Culture conditions were as described in Fig. 1. After amplification of
VH3 in a nested PCR, double-stranded PCR products were denatured
and separated on a native polyacrylamide gel. Lanes containing more
than two bands are indicated by arrows. Multiple bands (more than
two) were found more frequently in cultures containing IL-10+IL-
1b+IL-2 (a: lanes 1, 3 and 5) compared with IL-10+IL-7+IL-4 (b:
lane 5). Cloning and sequencing showed that the additional 2 bands in
(b) lane 5 were due to different VH3 germline genes. Additional bands
in (a) were due to in vitro mutations.
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of these clones sequenced. Also, five of the wells contained
sequences belonging to cells of different clonal origin, i.e. they
were of different germlines and VDJ-junctions (Table 3). The
one well that gave more than two bands in SSCP analysis of
cells cultured with IL-10+IL-7+IL-4 (lane 5, Fig. 3b)
contained sequences belonging to cells with a different clonal
origin. The number of expected clones with different germlines
was found to be consistent with calculations given for a 95%
confidence interval at the cell density analysed (Table 3).
Onset of somatic mutation in vitro
When DNA samples which did not differ in VH3 germline
configuration gave more than two bands in SSCP analysis the
additional bands were always of similar strength to the
originals (e.g. Fig. 3) This suggests that somatic mutations
were introduced during the first cycle(s) of division in culture.
Figure 4(a) outlines the distribution of confirmed muta-
tions in clones that were analysed. Two clones from well 2E
demonstrated three single base pair mutations and showed
some important features when compared to the nearest related
germline sequence: two of the mutations belonged to one clone
and the third to the other. This suggests a scenario illustrated in
Fig. 4(b) in which a cell division occurred before somatic
mutation of the V gene for that particular clone. This
contrasted with other clones in which sequence comparisons
suggested that mutations were likely to have occurred before
cell division (Fig. 4c).
Similarity between V gene mutations generated in vitro and
in vivo
Extended sequence analysis of the mutated clones was
performed and the position of mutations was compared to
sequence motifs previously described to be targets for somatic
hypermutation.29–31 The number of silent to replacement
mutations, and their positions, was also analysed. The overall
distribution of mutations is shown in Fig. 4(a) and Table 4. All
mutations found within the complementarity-determining
regions (CDR) represented replacement mutations, whereas
most of those in the FRs were silent (Table 4). These features
are reported to be characteristic of somatic hypermutation of
immunoglobulin V genes.4 Also, some of the mutations we
observed occurred in motifs which have been reported to be
targeted by the hypermutation process. For example, Table 4
shows that clone 5C which contains two GpA mutations
corresponds to a motif suggested by Dunn-Walters et al.29 in
which G is the target nucleotide for non-selected, out-of-frame
human immunoglobulin genes. The surrounding sequence in
clone 5C (mutated nucleotide in bold) is AGAG and TGAG,
respectively, while the suggested motif in this case would be
DGHD (D=A/G/T; H=A/C/T). Also, there was partial
agreement (three nucleotides out of four) with the suggested
RGYW motif30 for antigen-selected genes (clone 2E and 5B,
Table 4).
DISCUSSION
Activation of somatic hypermutation is tightly regulated in
vivo. The process is initiated in proliferating B cells in GCs but
Table 2. SSCP analysis of cultured GC B cells
Cytokines Expt.
No. of PCR products
(no. of wells screened) Cell density*
No. of wells giving
>2 bands/lane in SSCP
IL-10+IL-1b+IL-2 I 8 (30) 0.31 3
II 21 (60) 0.43 9
III 13 (60) 0.24 7
IV 25 (60) 0.53 13
IL-10+IL-7+IL-4 I 13 (60) 0.24 1
II 10 (30) 0.41 0
GC B cells were cultured for 5 days in the CD40 system supplemented with the cytokines indicated and then for further 5 days with the EL4 system. RNA
was amplified for VH3 immunoglobulin by nested RT–PCR and double stranded PCR products were analysed for mutations by SSCP. For cultures
containing IL-10+IL-7+IL-4 the frequency of samples giving >2 bands in SSCP was no more than would be expected by chance for seeding cultures with
>1 precursor (P>0.3), whereas for those from cultures containing IL-10+IL-1b+IL-2 it was significantly higher (P<0.001). When GC B cells were cultured
in the EL4 system alone 2/27 PCR positive wells from 180 screened gave lanes with >2 bands in SSCP (P>0.45).
*Cell density (the estimated number of cells per well at start of cultures) was calculated according to the Poisson distribution, using the proportion of VH3
positive wells.
Table 3. Sequence analysis of SSCP-positive clones to confirm mutations
Cytokines Experiment >2 bands/lane in SSCP
Clones with confirmed mutations
(no. per clone)
Different germlines
(95% CI)
IL-10+IL-1b+IL-2 I 3 2 (1,2) 1 (0.7–1.7)
II 9 4 (1,1,1,3) 5 (2.7–5.8)
IL-10+IL-7+IL-4 I 1 0 1 (0.9–2.2)
SSCP-positive clones were cloned, and re-confirmed with SSCP before sequencing.
The overall distribution of mutations is given in Fig. 4 and in Table 4.
The number of clones expected to contain different germlines according to Poisson distribution are given for a 95% confidence interval (CI) at the calculated
cell density.
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not those in extrafollicular sites.13 Study of ongoing mutation
in the GC B cells has hitherto been prevented by an inability to
maintain these cells in culture. We recently reported conditions
for the in vitro maintenance of proliferating human GC B cells
that retain the phenotypic characteristics of centroblasts18,20
and in the present study we used these culture conditions to
investigate whether signals that maintain proliferation and
phenotype also sustain active mutation.
The two cytokine combinations investigated were able to
support similar levels of CD40-dependent GC B-cell growth20
yet only one (IL-10+IL-1b+IL-2) was able to sustain active
mutation. Our finding argues against a simple requirement for
proliferating GC B cells (centroblasts) to remain in cycle for
mutation to continue. Taken together, our results suggest that
the process may be actively cytokine driven. As IL-10 was
common to both cytokine combinations this implicates IL-1b
and/or IL-2 as possible key regulatory cytokines in this regard.
IL-2 and IL-10 have each been identified at the mRNA level in
GC T cells and IL-1b in follicular dendritic cells at both the
mRNA and protein level.32 Tingible body macrophages that
are found in the GC dark zone are another possible source of
IL-1b. Soluble factors released by the CD32 fibroblast
transfectants used in the CD40 system contribute to the
cytokine-dependent maintenance of GC B cell proliferation20
and we cannot exclude the possibility that they may also play a
part in the observed mutational activity. However, as such
(a)
(b)
(c)
Figure 4. Distribution and origin of immunoglobulin V gene mutations arising in vitro. (a) The single nucleotide substitutions found
within the V region of the PCR-amplified immunoglobulin genes. Three point mutations were found in the two clones in well 2E.
Comparison with the nearest related germline sequence revealed that two of these mutations belonged to one of the two clones (2E1 in
b) and the third mutation to the other clone (2E2). This indicates a scenario outlined in (b), in which cell division occurred before
further accumulation of somatic mutations. In contrast, mutations in other clones are likely to have occurred before cell division (c).
The design of the nested PCR employed is also shown in (a): PCR I denotes the first, and PCR II the second amplifications. *indicates
a cell containing mutated IgVH3 genes.
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factors are common to both the mutating and nonmutating
conditions identified for GC B cells, their role – if any – must be
subsidiary only.
The ability of the cytokine combination IL-10+IL-1b+IL-
2 to sustain mutational activity was, de facto, CD40-dependent:
GC B cells could not be maintained in culture in the absence of
CD40 engagement.20 The dependence of mutational activity on
CD40 signals is consistent with current models of B-cell
development. First, to enter a GC reaction – the exclusive site
for somatic mutation in vivo – antigen-primed B cells must
engage cognate T cells in a CD40L-dependent manner.33 It is of
interest to note that in the reports to date describing the in vitro
induction of somatic mutation, either in B-cell lines or in
primary B-cell populations, all demonstrated a requirement for
activated T cells.34–36 Second, it has been suggested that having
entered a follicular reaction, differentiating centroblasts
forming the dark zone might sustain their proliferation by
means of autocrine, B-cell associated CD40L expressed, or
released, in the locality.37–39 Clearly, when established at the
limiting cell numbers needed for our analysis, any CD40
signalling that would normally be provided by juxtacrine
engagement in vivo would have to be provided exogenously
in vitro. Finally, centrocytes, the non-dividing progeny of
centroblasts, upon antigen-rescue, receive cognate signals from
CD40L-containing CD4+ T cells in the GC outer zone. The
delivery of a CD40 signal here is thought to direct a proportion
of the T-cell selected centrocytes to return to the dark zone
(DZ) as centroblasts and thereby undergo further rounds of
somatic mutation.33 Each of these can be considered, since the
cells we cultured were an approximately equal mix of
centroblasts and centrocytes.
In addition to a requirement for T cells, the reports
describing the induction of mutational activity in B cells de
novo have highlighted a strict dependence on B-cell receptor
(BCR) engagement.34–36 Our finding that, for GC B cells,
mutations can be sustained in the absence of BCR-derived
signals is likely to reflect the distinctive origin and biology of
these cells: centroblasts express, at best, low levels of surface
immunoglobulin and opportunities for productive engagement
of BCR on centroblasts by antigen in the follicular dendritic
cell (FDC)-poor dark zone in vivo would not only be scarce but
also inappropriate. Our findings indicate that a distinction
exists between signals that can initiate mutation and those that
maintain it. We cannot, however, exclude the possibility that
engaging the BCR on cultured GC cells may alter the mutation
rates observed, a possibility that – along with other considera-
tions – can now be examined.
As the SSCP analysis indicated that the mutation of IgV
genes in vitro was likely to have been confined to the first
cycle(s) of culture it is possible that the number of cell divisions
that occurred set a limit on the extent of mutations we
observed. The culture conditions we employed may not have
been optimal to maintain growth of single centroblasts nor
promote re-entry of centrocytes into cell cycle.40
Importantly, as RT–PCR-based SSCP was employed to
screen for mutations generated in vitro we verified that cultures
giving positive results had contained single cells by cloning and
sequence analysis of amplified DNA. We also excluded the
possibility of mutations arising from Taq polymerase errors:
cloned PCR products were always re-confirmed by SSCP
analysis before sequencing.
The characteristics of the mutations we observed in
cultured GC B cells (Table 4) were consistent with those
reported in situ, for example the preponderance of replacement
mutations within the CDRs and silent mutations in the FRs.
However, we have not yet analysed sufficient sequences to draw
firm conclusions regarding similarities with reported target
motifs. We are currently performing an extended study of
mutated clones from cultured GC B cells to analyse for motifs
in mutated immunoglobulin V genes.
The approach described here should enable further study
not only of the mechanisms of somatic hypermutation in the
cells in which the process occurs physiologically but also of
other molecular aspects of GC B-cell biology.
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Table 4. Sequence analysis of mutated clones
Clone Mutation
Position
(amino acid) Codon
Amino acid shift
(S or R*)
2E ApG FR2 (41) CCApCCG proppro (S)
CpT CDR2 (70) TCCpTTC serpphe (R)
CpG CDR3 (88) GCCpGGC alapgly (R)
5B ApG CDR2 (64) AAGpAGG lysparg (R)
5C GpA FR3 (82c) CTGpCTA{ leupleu (S)
GpA FR3 (71) AGApAAA argplys (R)
3E ApC FR3 (71) AGApCGA argparg (S)
4F ApG FR2 (41) CCApCCG proppro (S)
6F ApG CDR3 (87) AGApGGA argpgly (R)
*S, silent; R, replacement.
{The surrounding sequences in clone 5C (mutated nucleotide in bold) are AGAD and TGAG, while the motif for hypermutation suggested in 29 would be
DGHD (D=A/G/T; H=A/C/T).
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